Document:

Exhibit
10.73

 

THIS
WARRANT HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON
AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY
NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE
SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY
ACCEPTABLE TO THE COMPANY.

 

The
number of shares of common stock issuable upon exercise of this warrant may be less than the amounts set forth on the face hereof.

 

This
Warrant is issued pursuant to that certain Unit Purchase Agreement dated May [  ], 2021 by and between the Company and the Holder (as
defined below) (the “Purchase Agreement”). Capitalized terms used and not otherwise defined herein shall have the
meanings set forth for such terms in the Purchase Agreement. Receipt of this Warrant by the Holder shall constitute acceptance and agreement
to all of the terms contained herein.

 

No.
[●]

 

MARIZYME,
INC.

 

CLASS
B COMMON STOCK PURCHASE WARRANT

 

Marizyme,
Inc., a Nevada corporation (together with any corporation which shall succeed to or assume the obligations of Marizyme, Inc. hereunder,
the “Company”), hereby certifies that, for value received, [_________], a [_________] (the “Holder”),
is entitled, subject to the terms set forth below, to purchase from the Company at any time during the Exercise Period (as defined in
Section 9) up to [_____________] ([_______]) fully paid and non-assessable shares of Common Stock (as defined in Section 9),
at a purchase price per share equal to the Exercise Price (as defined in Section 9). The number of shares of Common Stock for
which this Common Stock Purchase Warrant (this “Warrant”) is exercisable and the Exercise Price are subject
to adjustment as provided herein.

 

1.
DEFINITIONS. Certain terms are used in this Warrant as specifically defined in Section 9.

 

2.
EXERCISE OF WARRANT.

 

2.1.
Exercise. This Warrant may be exercised prior to its expiration pursuant to Section 2.5 hereof by the Holder at any time
or from time to time during the Exercise Period, by submitting the form of subscription attached hereto (the “Exercise Notice”)
duly executed by the Holder, to the Company at its principal office, indicating whether the Holder is electing to purchase a specified
number of shares by paying the Aggregate Exercise Price as provided in Section 2.2 or is electing to exercise this Warrant as
to a specified number of shares pursuant to the net exercise provisions of Section 2.3. On or before the first Trading Day following
the date on which the Company has received the Exercise Notice, the Company shall transmit by electronic mail an acknowledgement of confirmation
of receipt of the Exercise Notice. Subject to Section 2.4, this Warrant shall be deemed exercised for all purposes as of the close
of business on the day on which the Holder has delivered the Exercise Notice to the Company. The Aggregate Exercise Price, if any, shall
be paid by wire transfer to the Company within five (5) Business Days of the date of exercise and prior to the time the Company issues
the certificates evidencing the shares issuable upon such exercise. In the event this Warrant is not exercised in full, the Company may,
at its expense, require the Holder, after such partial exercise, to promptly return this Warrant to the Company and the Company will
forthwith issue and deliver to or upon the order of the Holder a new Warrant or Warrants of like tenor, in the name of the Holder or
as the Holder (upon payment by the Holder of any applicable transfer taxes) may request, calling in the aggregate on the face or faces
thereof for the number of shares of Common Stock equal (without giving effect to any adjustment therein) to the number of such shares
called for on the face of this Warrant minus the number of such shares (without giving effect to any adjustment therein) for which this
Warrant shall have been exercised.

 

    	 

    	 

    

 

2.2.
Payment of Exercise Price by Wire Transfer. If the Holder elects to purchase a specified number of shares by paying the Aggregate
Exercise Price, the Holder shall pay such amount by wire transfer of immediately available funds to the account designated by the Company
in its acknowledgement of receipt of such Exercise Notice pursuant to Section 2.1.

 

2.3.
Net Exercise. If a registration statement covering the shares of Common Stock that are the subject of the Notice of Exercise (the
“Unavailable Warrant Shares”) is not available for the resale of such Unavailable Warrant Shares to the public or
upon exercise of this Warrant in connection with a Fundamental Transaction, the Holder may elect to exercise this Warrant by receiving
shares of Common Stock equal to the number of shares determined pursuant to the following formula:

 

X
= Y (A - B)

A

 

where,

 

	 	X
    =	the
    number of shares of Common Stock to be issued to Holder;
	 	 	 
	 	Y
    =	the
    number of shares of Common Stock as to which this Warrant is to be exercised (as indicated on the Exercise Notice);
	 	 	 
	 	A
    =	VWAP
    for the Trading Day immediately preceding the date of exercise; and
	 	 	 
	 	B
    =	the
    Exercise Price.

 

2.4.
Antitrust Notification. If the Holder determines, in its sole judgment upon the advice of counsel, that the issuance of any Warrant
Shares pursuant to the terms hereof would be subject to the provisions of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended (the “HSR Act”), the Company shall file as soon as practicable after the date on which the Company receives
notice from the Holder of the applicability of the HSR Act and a request to so file with the United States Federal Trade Commission and
the United States Department of Justice the notification and report form required to be filed by it pursuant to the HSR Act in connection
with such issuance.

 

2.5.
Termination. This Warrant shall terminate upon the earlier to occur of (i) exercise in full or (ii) the expiration of the Exercise
Period.

 

2.6
Company Exercise. At any time following the sixty (60) day anniversary of the final Closing Date or termination of the Offering,
if (i) the Company is listed on a national securities exchange or quoted on the over-the-counter markets, (ii) the Warrant Shares are
registered, which registration is and remains effective, or the Holder otherwise has the ability to trade the Warrant Shares without
restriction, (iii) the daily VWAP for the prior twenty (20) consecutive Trading Days is $8.00 or more (adjusted for splits and similar
distributions) and (iv) the daily trading volume is at least $1,000,000,000 during such thirty (30)-day period (the events set forth in clauses
(i) through (iv) above, collectively, the “Conditions”), then the Company can demand, upon five (5) Business Days’
notice that the Holder exercise this Warrant, pursuant to Section 2.1 hereof and subject to the limitations of Section 10,
as long as the Conditions remain in effect. The exercise referenced in this Section 2.6 shall be at the Exercise Price, including
any Exercise Price modified pursuant to the provisions of Section 5 hereof (exclusive of Section 5.4). For the avoidance
of doubt, in no instance may the Company demand an exercise under this Section 2.6 if there is no effective registration statement
covering the shares underlying the Warrant.

 

    	- 2 -

    	 

    

 

3.
REGISTRATION RIGHTS. The Holder’s registration rights are set forth in the Registration Rights Agreement.

 

4.
DELIVERY OF STOCK CERTIFICATES ON EXERCISE.

 

4.1.
Delivery of Exercise Shares. As soon as practicable after any exercise of this Warrant and in any event within two (2) Trading
Days thereafter (such date, the “Exercise Share Delivery Date”), the Company shall, at its expense (including the
payment by it of any applicable issue or stamp taxes), cause to be issued in the name of and delivered to the Holder, or as the Holder
may direct, a certificate or certificates evidencing the number of fully paid and non-assessable shares of Common Stock (which number
shall be rounded down to the nearest whole share in the event any fractional share may otherwise be issuable upon such exercise and the
Company shall pay a cash adjustment to the Holder in respect of such final fraction in an amount equal to such fraction multiplied by
the Exercise Price) to which the Holder shall be entitled on such exercise, in such denominations as may be requested by the Holder,
which certificate or certificates shall be free of restrictive and trading legends (except for any such legends as may be required under
the Securities Act). In lieu of delivering physical certificates for the shares of Common Stock issuable upon any exercise of this Warrant,
provided the Warrant Shares are not restricted securities and the Company’s transfer agent is participating in the Depository Trust
Company (“DTC”) Fast Automated Securities Transfer program or a similar program, upon request of the Holder, the Company
shall cause its transfer agent to electronically transmit such shares of Common Stock issuable upon exercise of this Warrant to the Holder
(or its designee), by crediting the account of the Holder’s (or such designee’s) broker with DTC through its Deposit Withdrawal
Agent Commission system (provided that the same time periods herein as for stock certificates shall apply) as instructed by the Holder
(or its designee).

 

4.2.
Compensation for Buy-In on Failure to Timely Deliver Exercise Shares. In addition to any other rights available to the Holder,
if the Company fails to cause its transfer agent to transmit to the Holder Exercise Shares pursuant to an exercise on or before the Exercise
Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise)
or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of
the Exercise Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall
(a) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions,
if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Exercise Shares
that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell
order giving rise to such purchase obligation was executed, and (b) at the option of the Holder, either reinstate the portion of the
Warrant and equivalent number of Exercise Shares for which such exercise was not honored (in which case such exercise shall be deemed
rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied
with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price
of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise
to such purchase obligation of $10,000, under clause (a) of the immediately preceding sentence the Company shall be required to pay the
Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In
and evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue a decree of specific performance
and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant
as required pursuant to the terms hereof.

 

    	- 3 -

    	 

    

 

4.3.
Charges, Taxes and Expenses. Issuance of Exercise Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Exercise Shares, all of which taxes and expenses shall be paid by
the Company, and such Exercise Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
provided, however, that in the event Exercise Shares are to be issued in a name other than the name of the Holder, this
Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto (the “Assignment Form”)
duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for
any transfer tax incidental thereto.

 

5.
CERTAIN ADJUSTMENT.

 

5.1.
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (a) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (b) subdivides outstanding shares of Common Stock into a larger number of shares, (c) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (d) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 5.1 shall become effective immediately after the record date
for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re-classification.

 

5.2
Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided,
however, that, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding
the beneficial ownership limitation provided for in Section 10, then the Holder shall not be entitled to participate in such Distribution
to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the
portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would
not result in the Holder exceeding the beneficial ownership limitation).

 

    	- 4 -

    	 

    

 

5.3
Fundamental Transaction. If, at any time while this Warrant is outstanding, (a) the Company effects any merger or consolidation
of the Company with or into another Person, (b) the Company effects any sale of all or substantially all of its assets in one or a series
of related transactions, (c) any tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which
holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property, or (d) the Company effects
any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property (each, a “Fundamental Transaction”), then, upon the closing
of a Fundamental Transaction and payment of the exercise price therefore (including at the election of the Holder by cashless exercise),
the Holder shall receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence
of such Fundamental Transaction, the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if
it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a
result of such merger, consolidation or disposition of assets by a holder of the number of shares of Common Stock for which this Warrant
is exercisable immediately prior to such event. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of
Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in
a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock
are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given
the same choice as to the Alternate Consideration it receives upon exercise of this Warrant upon the closing of such Fundamental Transaction.
The foregoing notwithstanding, if the Company effects any reclassification of the Common Stock or any compulsory share exchange, in each
case, into another security of the Company, this Warrant shall remain outstanding and the Holder shall be entitled to receive the Alternative
Consideration upon any subsequent exercise of this Warrant and the payment of the exercise price therefor. The terms of any agreement
pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply
with the provisions of this Section 5.3.

 

5.4
Calculations. All calculations under this Section 5 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 5, the number of shares of Common Stock deemed to be issued and outstanding as
of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding at
the close of the Trading Day on or, if not applicable, most recently preceding, such given date.

 

5.5
Notice to Holder.

 

(a)
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 5, the
Company shall promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement
of the facts requiring such adjustment.

 

    	- 5 -

    	 

    

 

(b)
Notice to Allow Exercise by Holder. If (i) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock; (ii) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock; (iii) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights; (iv) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or
substantially all of the assets of the Company, of any compulsory share exchange whereby the Common Stock is converted into other securities,
cash or property; or (v) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company; then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the
Warrant Register of the Company, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter specified,
a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or
warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend,
distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger,
sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the
Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or
any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice.
Subject to applicable law, the Holder is entitled to exercise this Warrant during the period commencing on the date of such notice to
the effective date of the event triggering such notice. Notwithstanding the foregoing, the delivery of the notice described in this Section
5.5 is not intended to and shall not bestow upon the Holder any voting rights whatsoever with respect to outstanding unexercised
Warrants.

 

6.
NO IMPAIRMENT. The Company will not, by amendment of the Articles of Incorporation or through any reorganization, transfer of
assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms
and in taking all such action as may be necessary or appropriate in order to protect the rights of the Holder against impairment. Without
limiting the generality of the foregoing, the Company (a) will not increase the par value of any shares of Common Stock receivable on
the exercise of this Warrant above the amount payable therefor on such exercise and (b) will take all such action as may be necessary
or appropriate in order that the Company may validly and legally issue fully paid and non-assessable shares of stock on the exercise
of this Warrant from time to time outstanding.

 

7.
NOTICES OF RECORD DATE. In the event of:

 

(a)
any taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof who
are entitled to receive any dividend or other distribution, or any right to subscribe for, purchase or otherwise acquire any shares of
stock of any class or any other securities or property, or to receive any other right;

 

(b)
any capital reorganization of the Company, any reclassification or recapitalization of the capital stock of the Company or any transfer
of all or substantially all the assets of the Company to or any consolidation or merger of the Company with or into any other Person
or any other Change of Control; or

 

(c)
any voluntary or involuntary dissolution, liquidation or winding-up of the Company;

 

then,
and in each such event, the Company will mail or cause to be mailed to the Holder a notice specifying (i) the date on which any such
record is to be taken for the purpose of such dividend, distribution or right, and stating the amount and character of such dividend,
distribution or right, or (ii) the date on which any such reorganization, reclassification, recapitalization, transfer, consolidation,
merger, dissolution, liquidation or winding-up is anticipated to take place, and the time, if any is to be fixed, as of which the holders
of record of Common Stock shall be entitled to exchange their shares of Common Stock for securities or other property deliverable on
such reorganization, reclassification, recapitalization, transfer, consolidation, merger, dissolution, liquidation or winding-up. Such
notice shall be mailed at least fifteen (15) days prior to the date specified in such notice on which any such action is to be taken.

 

    	- 6 -

    	 

    

  

8.
RESERVATION OF STOCK ISSUABLE ON EXERCISE OF WARRANT; REGULATORY COMPLIANCE.

 

8.1.
Reservation of Stock Issuable on Exercise of Warrant. The Company shall at all times while this Warrant shall be outstanding,
reserve and keep available out of its authorized but unissued Common Stock, such number of shares of Common Stock as shall from time
to time be sufficient to effect the exercise of all or any portion of the Warrant Shares (disregarding for this purpose any and all limitations
of any kind on such exercise). The Company shall, from time to time in accordance with Chapter 78 of the Nevada Revised Statutes, increase
the authorized number of shares of Common Stock or take other effective action if at any time the unissued number of authorized shares
shall not be sufficient to satisfy the Company’s obligations under this Section 8.

 

8.2.
Regulatory Compliance. If any shares of Common Stock to be reserved for the purpose of exercise of the Warrant Shares require
registration or listing with or approval of any Governmental Authority, stock exchange or other regulatory body under any federal or
state law or regulation or otherwise before such shares may be validly issued or delivered upon exercise, the Company shall, at its sole
cost and expense, in good faith and as expeditiously as possible, secure such registration, listing or approval, as the case may be.

 

8.3.
Stockholder Approval. The Company shall not be required to issue any Warrant Shares if such issuance would cause the Company to
be required to obtain the Stockholder Approval either pursuant to the rules and regulations of the Trading Market or otherwise until
such Stockholder Approval has been obtained.

 

9.
DEFINITIONS. As used herein the following terms, unless the context otherwise requires, have the following respective meanings:

 

“Affiliate”
means a Person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control
with, the Person specified, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Aggregate
Exercise Price” means, in connection with the exercise of this Warrant at any time, an amount equal to the product obtained
by multiplying (i) the Exercise Price times (ii) the number of shares of Common Stock for which this Warrant is being exercised at such
time.

 

“Articles
of Incorporation” means the Company’s Articles of Incorporation.

 
“Business
Day” means any day other than a Saturday, Sunday or any other day on which the Federal Reserve Bank of New York is closed in
New York City.

 

“Change
of Control” has the meaning set forth in the Purchase Agreement.

 

“Common
Stock” means (i) the Company’s Common Stock, $0.001 par value per share, and (ii) any other securities into which or
for which any of the securities described in clause (i) above have been converted or exchanged pursuant to a plan of recapitalization,
reorganization, merger, sale of assets or otherwise.

 

“Convertible
Securities” means any debt, equity or other securities that are, directly or indirectly, convertible into or exchangeable for
Common Stock.

 

    	- 7 -

    	 

    

 

“Customary
Antidilution Adjustments” means customary anti-dilution protection for stock splits, stock dividends, stock combinations, recapitalizations
and similar transactions.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder from time
to time in effect.

 

“Exercise
Period” means the period commencing on the Issue Date and ending 11:59 P.M. (New York City time) on the five-year anniversary
of the Issue Date or earlier closing of a Fundamental Transaction (other than a Fundamental Transaction of the type described in clause
(d) of the definition thereof resulting in the conversion into or exchange for another security of the Company).

 

“Exercise
Price” means $5.00 per share.

 

“Exercise
Shares” means the shares of Common Stock for which this Warrant is then being exercised.

 

“Fair
Market Value” means, with respect to any security or other property, the fair market value of such security or other property
as determined by the Board of Directors, acting in good faith. “Governmental Authority” means the government of the
United States or any other nation, or of any political subdivision thereof, whether state or local, and any agency, authority, instrumentality,
regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative
powers or functions of or pertaining to government (including any supra-national bodies such as the European Union or the European Central
Bank).

 

“Floor
Price” means $1.00 per share (subject to Customary Antidilution Adjustments.

 

“Issue
Date” means May [  ], 2021.

 

“Next
Round Securities” means equity or equity equivalent securities sold in a Company equity financing while the Note is outstanding.

 

“Note”
means the 10% secured convertible promissory note issued by the Company to the Holder pursuant to the Purchase Agreement.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 
“Purchase
Agreement” has the meaning set forth on the first page of this Warrant.

 

“Registration
Rights Agreement” means the Registration Rights Agreement, dated as of May [  ], 2021 (as the same may be amended from time
to time), by and between the Company and the Holder.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder from time to time in
effect.

 

“Subsidiary”
means, as of any time of determination and with respect to any Person, any United States corporation, partnership, limited liability
company or limited liability partnership, all of the stock (or other equity interest) of every class of which, except directors’
qualifying shares (or any equivalent), shall, at such time, be owned by such Person either directly or through Subsidiaries and of which
such Person or a Subsidiary shall have 100% control thereof, except directors’ qualifying shares. Unless the context otherwise
clearly requires, any reference to a “Subsidiary” is a reference to a Subsidiary of the Company.

 

    	- 8 -

    	 

    

  

“Trading
Day” means a day on which the Common Stock is traded on a Trading Market.

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock (or any other common stock of any other Person
that references the Trading Market for its common stock) is listed or quoted for trading on the date in question: the OTC Bulletin Board,
The NASDAQ Global Market, The NASDAQ Global Select Market, The NASDAQ Capital Market, the New York Stock Exchange, NYSE Arca, the NYSE
MKT, or the OTCQX Marketplace, the OTCQB Marketplace, the OTC Pink Marketplace or any other tier operated by OTC Markets Group Inc. (or
any successor to any of the foregoing).

 

“VWAP”
means, for or as of any date, the dollar volume-weighted average price for such security on the Trading Market (or, if the Trading Market
is not the principal trading market for such security, then on the principal securities exchange or securities market on which such security
is then traded) during the period beginning at 9:30 a.m., New York time, and ending at 4:02 p.m., New York time, as reported by Bloomberg
through its “HP” function (set to weighted average) or, if the foregoing does not apply, the dollar volume-weighted average
price of such security in the over-the-counter market on the electronic bulletin board for such security during the period beginning
at 9:30 a.m., New York time, and ending at 4:02 p.m., New York time, as reported by Bloomberg, or, if no dollar volume-weighted average
price is reported for such security by Bloomberg for such hours, the average of the highest closing bid price and the lowest closing
ask price of any of the market makers for such security as reported in the “pink sheets” by OTC Markets Group Inc. (formerly
Pink Sheets LLC). If the VWAP cannot be calculated for such security on such date on any of the foregoing bases, the VWAP of such security
on such date shall be the fair market value as mutually determined by the Company and the Holder. All such determinations shall be appropriately
adjusted for any stock dividend, stock split, stock combination, recapitalization or other similar transaction during such period.

 

“Warrant
Shares” means collectively the shares of Common Stock of the Company issuable upon exercise of this Warrant in accordance with
its terms, as such number may be adjusted pursuant to the provisions thereof.

 

    	- 9 -

    	 

    

 

10.
LIMITATION ON BENEFICIAL OWNERSHIP. Notwithstanding anything to the contrary contained herein, the Holder shall not be entitled
to receive shares of Common Stock or other securities (together with Common Stock, “Equity Interests”) upon exercise
of this Warrant to the extent (but only to the extent) that such exercise or receipt would cause the Holder Group to become, directly
or indirectly, a “beneficial owner” (within the meaning of Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder) of a number of Equity Interests of a class that is registered under the Exchange Act which exceeds the Maximum
Percentage (as defined below) of the Equity Interests of such class that are outstanding at such time. Any purported delivery of Equity
Interests in connection with the exercise of the Warrant prior to the termination of this restriction in accordance herewith shall be
void and have no effect to the extent (but only to the extent) that such delivery would result in the Holder Group becoming the beneficial
owner of more than the Maximum Percentage of the Equity Interests of a class that is registered under the Exchange Act that is outstanding
at such time. If any delivery of Equity Interests owed to the Holder following exercise of this Warrant is not made, in whole or in part,
as a result of this limitation, the Company’s obligation to make such delivery shall not be extinguished and the Company shall
deliver such Equity Interests as promptly as practicable after the Holder gives notice to the Company that such delivery would not result
in such limitation being triggered or upon termination of the restriction in accordance with the terms hereof. To the extent limitations
contained in this Section 10 apply, the determination of whether this Warrant is exercisable and of which portion of this Warrant
is exercisable shall be the sole responsibility and in the sole determination of the Holder, and the submission of an Exercise Notice
shall be deemed to constitute the Holder’s determination that the issuance of the full number of Warrant Shares requested in the
Exercise Notice is permitted hereunder, and neither the Company nor any Warrant agent shall have any obligation to verify or confirm
the accuracy of such determination. For purposes of this Section 10, (i) the term “Maximum Percentage” shall
mean 4.99%; provided, that if at any time after the date hereof the Holder Group beneficially owns in excess of 4.99% of any class of
Equity Interests in the Company that is registered under the Exchange Act (excluding any Equity Interests deemed beneficially owned by
virtue of this Warrant or the Note), then the Maximum Percentage shall automatically increase to 9.99% so long as the Holder Group owns
in excess of 4.99% of such class of Equity Interests (and shall, for the avoidance of doubt, automatically decrease to 4.99% upon the
Holder Group ceasing to own in excess of 4.99% of such class of Equity Interests); and (ii) the term “Holder Group”
shall mean the Holder plus any other Person with which the Holder is considered to be part of a group under Section 13 of the Exchange
Act or with which the Holder otherwise files reports under Sections 13 and/or 16 of the Exchange Act. In determining the number of Equity
Interests of a particular class outstanding at any point in time, the Holder may rely on the number of outstanding Equity Interests of
such class as reflected in (x) the Company’s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission, as the case may be, (y) a more recent public announcement by the Company or (z) a more recent
notice by the Company or its transfer agent to the Holder setting forth the number of Equity Interests of such class then outstanding.
For any reason at any time, upon written or oral request of the Holder, the Company shall, within one (1) Trading Day of such request,
confirm orally and in writing to the Holder the number of Equity Interests of any class then outstanding. Anything herein to the contrary,
any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company.
The provisions of this Section 10 shall be construed, corrected and implemented in a manner so as to effectuate the intended beneficial
ownership limitation herein contained.

 

11.
REGISTRATION AND TRANSFER OF WARRANT.

 

11.1.
Registration of Warrant. The Company shall register and record transfers, exchanges, reissuances and cancellations of this Warrant,
upon the records to be maintained by the Company for that purpose, in the name of the record holder hereof from time to time. The Company
may deem and treat the registered holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary. The Company shall be entitled to rely and held harmless
in acting or refraining from acting in reliance upon, any notices, instructions or documents it believes in good faith to be from an
authorized representative of the Holder.

 

11.2
Transferability. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form of assignment (the “Assignment Notice”) attached hereto duly
executed by the Holder or its agent or attorney. The Company may require the transferor thereof to provide to the Company an opinion
of counsel selected by the transferor, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the
effect that such transfer does not require registration of the transferred Warrant under the Securities Act. Upon such surrender, the
Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such Assignment Notice, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant
not so assigned, and this Warrant shall promptly be cancelled. This Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Exercise Shares without having a new Warrant issued.

 

    	- 10 -

    	 

    

  

11.3.
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 11.2, as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for this Warrant or Warrants to
be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue
Date and shall be identical with this Warrant except as to the number of Exercise Shares issuable pursuant thereto.

 

12.
LOSS, THEFT, DESTRUCTION OR MUTILATION OF WARRANT. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Exercise Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of this Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.

 

13.
REMEDIES. The Company stipulates that the remedies at law of the Holder in the event of any default or threatened default by the
Company in the performance of or compliance with any of the terms of this Warrant are not and will not be adequate, and that such terms
may be specifically enforced by a decree for the specific performance of any agreement contained herein or by an injunction against a
violation of any of the terms hereof or otherwise.

 

14.
NO RIGHTS AS A STOCKHOLDER. Except as otherwise specifically provided herein, the Holder, solely in such Person’s capacity
as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company
for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person’s capacity
as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any
corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise),
receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Exercise
Shares.

 

15.
NOTICES. All notices, requests, demands and other communications that are required or may be given pursuant to the terms of this
Warrant shall be in writing and shall be deemed delivered (i) on the date of delivery when delivered by hand on a Business Day during
normal business hours or, if delivered on a day that is not a Business Day or after normal business hours, then on the next Business
Day, (ii) on the date of transmission when sent by facsimile transmission or email during normal business hours on a Business Day with
telephone confirmation of receipt or, if transmitted on a day that is not a Business Day or after normal business hours, then on the
next Business Day, or (iii) on the second Business Day after the date of dispatch when sent by a reputable courier service that maintains
records of receipt. The addresses for notice shall be as set forth in the Purchase Agreement.

 

16.
CONSENT TO AMENDMENTS. Any term of this Warrant may be amended, and the Company may take any action herein prohibited, or compliance
therewith may be waived, only if the Company shall have obtained the written consent (and not without such written consent) to such amendment,
action or waiver from the Holder. No course of dealing between the Company and the Holder nor any delay in exercising any rights hereunder
shall operate as a waiver of any rights of the Holder.

 

17.
MISCELLANEOUS. In case any provision of this Warrant shall be invalid, illegal or unenforceable, or partially invalid, illegal
or unenforceable, the provision shall be enforced to the extent, if any, that it may legally be enforced and the validity, legality and
enforceability of the remaining provisions shall not in any way be affected or impaired thereby. If any provision of this Warrant is
found to conflict with the Purchase Agreement, the provisions of this Warrant shall prevail. If any provision of this Warrant is found
to conflict with the Note, the provisions of the Note shall prevail. THIS WARRANT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH,
AND THE RIGHTS OF THE PARTIES SHALL BE GOVERNED BY, THE INTERNAL LAW OF THE STATE OF NEW YORK EXCLUDING CHOICE-OF-LAW PRINCIPLES OF THE
LAW OF SUCH STATE THAT WOULD PERMIT THE APPLICATION OF THE LAWS OF A JURISDICTION OTHER THAN SUCH STATE. The headings in this Warrant
are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof.

 

[Remainder
of Page Intentionally Left Blank]

 

    	- 11 -

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its duly authorized officer.

 

Dated
as of May [  ], 2021

 

	 	marizyme,
    INC.
	 	 	 
	 	By:	               
	 	 	 
	 	Name:	 
	 	 	 
	 	Title:	 

 

    	- 12 -

    	 

    

 

FORM
OF SUBSCRIPTION

 

(To
be signed only on exercise

of
attached Warrant)

 

	TO:	Marizyme,
    Inc.

 

1.
The undersigned Holder of the attached Warrant hereby elects to exercise its purchase right under such Warrant to purchase shares of
Common Stock of Marizyme, Inc., a Nevada corporation (the “Company”), as follows (check one or more, as applicable):

 

	 	[  ]	to
    exercise the Warrant to purchase __________ shares of Common Stock and to pay the Aggregate Exercise Price therefor by wire transfer
    of United States funds to the account of the Company, which transfer has been made prior to or as of the date of delivery of this
    Form of Subscription pursuant to the instructions of the Company;
	 	 	 
	 	 	and/or
	 	 	 
	 	[  ]	to
    exercise the Warrant with respect to ____________ shares of Common Stock pursuant to the net exercise provisions specified in Section
    2.3 of the Warrant.

 

2.
In exercising this Warrant, the undersigned Holder hereby confirms and acknowledges that the shares of Common Stock are being acquired
solely for the account of the undersigned and not as a nominee for any other party, and for investment, and that the undersigned shall
not offer, sell or otherwise dispose of any such shares of Common Stock except under circumstances that will not result in a violation
of the Securities Act or any state securities laws. The undersigned hereby further confirms and acknowledges that it is an “accredited
investor”, as that term is defined under the Securities Act.

 

3.
Please issue a stock certificate or certificates representing the appropriate number of shares of Common Stock in the name of the undersigned
or in such other name(s) as is specified below:

 

	Name:	 	 
	 	 	 
	Address:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	TIN:	 	 

 

	 	 	Dated:	 	 
	(Signature
    must conform exactly to name of Holder as specified on the face of the Warrant)	 	 	 	 

 

    	 

    	 

    

 

FORM
OF ASSIGNMENT

(To
be signed only on transfer of Warrant)

 

For
value received, the undersigned hereby sells, assigns, and transfers unto ________________ the right represented by the within Warrant
to purchase shares of Common Stock of Marizyme, Inc., a Nevada corporation, to which the within Warrant relates, and appoints _________________
attorney to transfer such right on the books of Marizyme, Inc., with full power of substitution in the premises.

 

	 	 	 	[insert
    name of Holder]
	 	 	 	 	 
	Dated:	 	 	By:	 
	 	 	 	 	 
	 	 	 	Title:	 
	 	 	 	 	 
	 	 	 	[insert
    address of Holder]
	 	 	 	 	 
	Signed
    in the presence of:Exhibit
10.74

 

PLACEMENT
AGENCY AGREEMENT

 

May
[__], 2021

 

Univest
Securities LLC

Investment
Banking

375
Park Avenue, 15th Fl.

New
York, New York 10152

 

Ladies
and Gentlemen:

 

Subject
to the terms and conditions herein (this “Agreement”) and the Transaction Documents (defined below), Marizyme, Inc.,
a Nevada (the “Company”), hereby agrees to sell units consisting of secured convertible promissory notes in the aggregate
principal amount of $TEN MILLION ($10,000,000) DOLLARS in the form attached as Exhibit A (the “Note”), together
with two classes of warrants (“Warrants”) to purchase shares of common stock, par value $0.001 per share (the “Common
Stock”), of the Company (the “Warrant Shares”) directly to one or more investors (each, an “Investor”
and, collectively, the “Investors”) through Univest Securities LLC (the “Placement Agent”), as
placement agent. The Securities (as defined below) shall be offered and sold pursuant to Section 4(a)(2) under the Securities Act of
1933, as amended (the “Securities Act”). The documents executed and delivered by the Company and the Investors in
connection with the Offering (as defined below), including, without limitation, a unit purchase agreement (the “Purchase Agreement”),
the Note, the Warrants, and a security agreement shall be collectively referred to herein as the “Transaction Documents.”
The Placement Agent may retain other brokers or dealers to act as sub-agents or selected-dealers on its behalf in connection with the
Offering (as defined below). The Units, including the Notes and the shares of Common Stock issuable upon conversion of the Notes (the
“Conversion Shares”), the Class A Warrants, Class B Warrants and the Warrant Shares are hereafter collectively referred
to as the “Securities.”

 

The
Company hereby confirms its agreement with the Placement Agent as follows:

 

Section
1. Agreement to Act as Placement Agent.

 

(a)
On the basis of the representations, warranties and agreements of the Company herein contained, and subject to all the terms and conditions
of this Agreement, the Placement Agent shall be the exclusive Placement Agent in connection with the offering and sale by the Company
of the Securities pursuant to Section 4(a)(2) under the Securities Act, with the terms of such offering (the “Offering”)
to be subject to market conditions and negotiations between the Company, the Placement Agent and the prospective Investors. The Placement
Agent will act on a reasonable best efforts basis and the Company agrees and acknowledges that there is no guarantee of the successful
placement of the Securities, or any portion thereof, in the prospective Offering. Under no circumstances will the Placement Agent or
any of its “Affiliates” (as defined below) be obligated to underwrite or purchase any of the Securities for its own account
or otherwise provide any financing. The Placement Agent shall act solely as the Company’s agent and not as principal. The Placement
Agent shall have no authority to bind the Company with respect to any prospective offer to purchase Securities and the Company shall
have the sole right to accept offers to purchase Securities and may reject any such offer, in whole or in part. Subject to the terms
and conditions hereof, payment of the purchase price for, and delivery of, the Securities shall be made at one or more closings (each
a “Closing” and the date on which each Closing occurs, a “Closing Date”). As compensation for services
rendered, on each Closing Date, the Company shall pay to the Placement Agent the fees and expenses set forth below:

 

	 	(i)	A
    cash fee equal to 8% of the gross proceeds received by the Company from the sale of the Securities at the Closing of the Offering
    to Investors.
	 	 	 
	 	(ii)	The
    Company also agrees to pay to the Placement Agent $50,000 if the gross amount raised is more than $6 Million; provided, however,
    that in the event that the Offering is terminated, the Company agrees to reimburse the Placement Agent pursuant to Section 6 hereof.

 

    	 

    	 

    

 

(b)
The Company hereby agrees to issue to the Placement Agent (and/or its designees) on the Closing Date, upon payment of $100.00 by the
Placement Agent on the Closing Date, warrants (“Placement Agent’s Warrants”) to purchase that number of shares
of Common Stock equal to 8% of the aggregate number of Conversion Shares placed in the Offering. The Placement Agent’s Warrant
agreement shall be exercisable, in whole or in part, commencing on the final Closing Date and shall be exercisable for a period of five
years. In the event that there is not an effective registration statement permitting for the resale of the shares underlying the Placement
Agent’s Warrants, the Placement Agent Warrant’s shall be exercisable on a cashless basis. The Placement Agent’s Warrant
Agreement and the shares of Common Stock issuable upon exercise thereof (the “PA Warrant Shares”) are hereinafter
referred to together as the “Placement Agent’s Securities.”

 

(c)
The term of the Placement Agent’s exclusive engagement will be until the completion of the Offering (the “Exclusive Term”);
provided, however, that a party hereto may terminate the engagement with respect to itself at any time upon fifteen (15)
days written notice to the other parties (provided that no such notice may be given until August 31, 2021 except in the case of termination
for cause). Notwithstanding anything to the contrary contained herein, the provisions concerning confidentiality, indemnification and
contribution contained herein and the Company’s obligations contained in the indemnification provisions will survive any expiration
or termination of this Agreement, and the Company’s obligation to pay fees actually earned and payable and to reimburse expenses
actually incurred and reimbursable pursuant to Section 1 hereof and which are permitted to be reimbursed under FINRA Rules, will survive
any expiration or termination of this Agreement. Nothing in this Agreement shall be construed to limit the ability of the Placement Agent
or its Affiliates to pursue, investigate, analyze, invest in, or engage in investment banking, financial advisory or any other business
relationship with Persons (as defined herein) other than the Company. As used herein (i) “Persons” means an individual
or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock
company, government (or an agency or subdivision thereof) or other entity of any kind and (ii) “Affiliate” means any
Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with
a Person as such terms are used in and construed under Rule 405 under the Securities Act.

 

Section
2. Representations and Warranties. The Company represents and warrants to the Placement Agent, as of the date hereof and as of the
Closing Date, all of the representations, warranties and agreements of the Company that were made by the Company to the Investor (as
defined in the Purchase Agreement) in Section 3 of the Purchase Agreement are true and correct with the same force and effect as of the
date hereof and as of the Closing Date as if made on the date hereof and each Closing Date, and that such representations and warranties
set forth in Section 3 thereof are hereby incorporated by reference herein. The Company agrees to all of the agreements and covenants
with respect to the Company in Section 5 of the Purchase Agreement with respect to the Placement Agent and that such agreements and covenants
set forth in Section 5 thereof are incorporated by reference herein. In addition to the foregoing, the Company represents and warrants
to the Placement Agent that:

 

(a)
(i) the Company has full right, power and authority to enter into this Agreement, to issue the Placement Agent’s Warrants and to
perform all of its obligations hereunder and consummate the transactions contemplated hereby and thereby; (ii) this Agreement and the
Placement Agent’s Warrant each has been duly authorized and executed and constitutes a legal, valid and binding agreement of such
party enforceable in accordance with its terms; (iii) the execution and delivery of this Agreement and the Placement Agent’s Warrants
and the consummation of the transactions contemplated hereby and thereby (including without limitation, the issuance of the Warrants
and the issuance and reservation for issuance of the PA Warrant Shares issuable upon exercise thereof) have been duly authorized by the
Company’s Board of Directors and no further consent or authorization of the Company, its Board of Directors, or its shareholders
is required; (iv) the execution and delivery of this Agreement and the Placement Agent’s Warrants and the consummation of the transactions
contemplated hereby and thereby does not conflict with or result in a breach of (x) the Company’s articles of incorporation or
bylaws or other charter documents, (y) any agreement to which the Company is a party or by which any of its property or assets is bound
or (z) any of the other items described in Sections 3.2 and 3.3 of the Purchase Agreement.

 

    	 

    	 

    

 

(b)
All disclosure provided by the Company to the Placement Agent regarding the Company, its business and the transactions contemplated hereby,
taken together with all reports, schedules, forms, statements and other documents required to be filed by it with the Securities and
Exchange Commission (the “Commission”) pursuant to the reporting requirements of the Exchange Act (all of the foregoing
filed prior to the date hereof and all exhibits included therein and financial statements and schedules thereto and documents (other
than exhibits to such documents) incorporated by reference therein, being hereinafter referred to herein as the “SEC Filings”),
is true and correct in all material aspects and does not contain any untrue statement of a material fact or omit to state any material
fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading.
To the best of the Company’s knowledge and belief, other than the current capital raising (of which this Agreement forms part),
no event or circumstance has occurred or information exists with respect to the Company or its business, properties, prospects, operations
or financial conditions, which, under the applicable laws, rules or regulations of the Commission, requires public disclosure or announcement
by the Company but which has not been so publicly announced or disclosed.

 

(c)
The Company has not taken and will not take any action, directly or indirectly, so as to cause the Offering to fail to be entitled to
rely upon the exemption from registration afforded by Section 4(a)(2) of the Securities Act. In effecting the Offering, the Company agrees
to comply in all material respects with applicable provisions of the Securities Act and any regulations thereunder and any applicable
laws, rules, regulations and requirements (including, without limitation, all U.S. state law and all national, provincial, city or other
legal requirements).

 

(d)
Issuance of Placement Agent’s Warrant and PA Warrant Shares. The PA Warrant Shares are, or at the consummation of the Offering
will be, duly authorized and reserved for issuance and, upon exercise of the Placement Agent’s Warrants in accordance with its
respective terms, will be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims and encumbrances with
respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Company and
will not impose personal liability upon the holder thereof.

 

Section
3. Delivery and Payment. Each Closing shall occur at the offices of Sullivan & Worcester, LLP, 405 1633 Broadway, 32nd
Floor, New York, New York 10019 (or at such other place as shall be agreed upon by the Placement Agent and the Company) (“Placement
Agent Counsel”). Subject to the terms and conditions hereof, at each Closing payment of the purchase price for the Securities
sold on such Closing Date shall be made by Federal Funds wire transfer, against delivery of such Securities, and such Securities shall
be registered in such name or names and shall be in such denominations, as the Placement Agent may request at least one (1) Business
Day (as defined in the Purchase Agreement) before the time of purchase.

 

Deliveries
of the documents with respect to the purchase of the Securities, if any, shall be made at the offices of Placement Agent Counsel. All
actions taken at a Closing shall be deemed to have occurred simultaneously.

 

Section
4. Covenants and Agreements of the Company. The Company further covenants and agrees with the Placement Agent as follows:

 

(a)
Blue Sky Compliance. The Company will cooperate with the Placement Agent and the Investors in endeavoring to qualify the Securities
for sale under the securities laws of such jurisdictions (United States and foreign) as the Placement Agent and the Investors may reasonably
request and will make such applications, file such documents, and furnish such information as may be reasonably required for that purpose,
provided the Company shall not be required to qualify as a foreign corporation or to file a general consent to service of process in
any jurisdiction where it is not now so qualified or required to file such a consent, and provided further that the Company shall not
be required to produce any new disclosure document other than the Transaction Documents. The Company will, from time to time, prepare
and file such statements, reports and other documents as are or may be required to continue such qualifications in effect for so long
a period as the Placement Agent may reasonably request for distribution of the Securities. The Company will advise the Placement Agent
promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Securities for offering, sale
or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of
any order suspending such qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof
at the earliest possible moment.

 

    	 

    	 

    

 

(b)
Amendments and Supplements to the Transaction Documents and Other Matters. The Company will comply with the Securities Act and
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations of the Commission
thereunder, so as to permit the completion of the distribution of the Securities as contemplated in this Agreement and the Transaction
Documents. If, prior to the termination of the Offering, any event shall occur as a result of which, in the judgment of the Company or
in the opinion of the Placement Agent or Placement Agent Counsel, it becomes necessary to amend or supplement the Transaction Documents
in order to make the statements therein, in the light of the circumstances under which they were made, as the case may be, not misleading,
or if it is necessary at any time to amend or supplement the Transaction Documents, the Company will promptly prepare and furnish at
its own expense to the Placement Agent and to dealers, an appropriate amendment or supplement to the Transaction Documents that is necessary
in order to make the statements therein as so amended or supplemented, in the light of the circumstances under which they were made,
as the case may be, not misleading, or so that the Transaction Documents, as so amended or supplemented, will comply with applicable
laws related to the Offering. Before amending or supplementing Transaction Documents in connection with the Offering, the Company will
furnish the Placement Agent with a copy of such proposed amendment or supplement and will not disseminate any such amendment or supplement
to which the Placement Agent reasonably objects. Notwithstanding any provision of this Section 4(b), the Company and its counsel shall
be afforded a reasonable opportunity to demonstrate why such amendment or supplement may not be necessary or advisable.

 

(c)
Copies of any Amendments and Supplements to the Transaction Documents. The Company will furnish the Placement Agent, without charge,
during the period beginning on the date hereof and ending on the later of the last Closing Date of the Offering, as many copies of the
Transaction Documents and any amendments and supplements thereto as the Placement Agent may reasonably request.

 

(d)
Reservation of Securities. The Company shall maintain a reserve from its duly authorized shares of Common Stock a sufficient number
of shares of Common Stock for issuance pursuant to the full exercise of the Placement Agent’s Warrant.

 

(e)
Transfer Agent. The Company will maintain, at its expense, a registrar and transfer agent for the Common Stock.

 

(f)
Registration of Securities; Exchange Approval. The Common Stock is registered under the Exchange Act and, as of the Closing Date,
the Conversion Shares, the Warrant Shares and PA Warrant Shares shall be, if and as applicable, either eligible for quotation on the
OTC markets or listed and admitted and authorized for trading on the Nasdaq Stock market or other applicable U.S. national exchange (the
“Trading Market”) (subject to any restrictions or conditions that may be imposed by the Trading Market or other applicable
U.S. national exchange) and satisfactory evidence of such action shall have been provided to the Placement Agent. For a period of three
(3) years, the Company shall take no action designed to, or likely to have the effect of terminating the registration of the Common Stock
under the Exchange Act or, if appliable, delisting or suspending from trading or quotation, as applicable, the Common Stock from the
Trading Market or other applicable U.S. national exchange and the Company has not received any information suggesting that the Commission
or the Trading Market or other U.S. applicable national exchange is contemplating terminating such registration, quotation, or listing.

 

(g)
Additional Documents. The Company will enter into any subscription, purchase or other customary agreements as the Placement
Agent or the Investors reasonably deem necessary or appropriate to consummate the Offering, all of which will be in form and substance
reasonably acceptable to the Placement Agent and the Investors. The Company agrees that the Placement Agent may rely upon, and each is
a third-party beneficiary of, the representations and warranties, and applicable covenants, set forth in any such purchase, subscription
or other agreement with Investors in the Offering.

 

    	 

    	 

    

 

(h)
No Manipulation of Price. The Company will not take, directly or indirectly, any action designed to cause or result in,
or that has constituted or might reasonably be expected to constitute, the stabilization or manipulation of the price of any securities
of the Company.

 

(i)
Acknowledgment. The Company acknowledges that any advice given by the Placement Agent to the Company is solely for the benefit
and use of the Board of Directors of the Company and may not be used, reproduced, disseminated, quoted or referred to, without the Placement
Agent’s prior written consent.

 

Section
5. Conditions of the Obligations of the Placement Agent. The obligations of the Placement Agent hereunder shall be subject to the
accuracy of the representations and warranties on the part of the Company set forth in Section 2 hereof, in each case as of the date
hereof and as of each Closing Date as though then made, to the timely performance by each of the Company of its covenants and other obligations
hereunder on and as of such dates, and to each of the following additional conditions:

 

(a)
No Untrue Statements. The Placement Agent shall not have discovered and disclosed to the Company on or prior to the Closing Date
that the SEC Filings contains an untrue statement of a fact which, in the opinion of Placement Agent’s Counsel, is material or
omits to state any fact which, in the opinion of such counsel, is material and is required to be stated therein or is necessary to make
the statements therein not misleading.

 

(b)
Compliance with Regulatory Requirements. No order having the effect of ceasing or suspending the distribution of the Securities
or any other securities of the Company shall have been issued by any securities commission, securities regulatory authority or stock
exchange and no proceedings for that purpose shall have been instituted or shall be pending or, to the knowledge of the Company, contemplated
by any securities commission, securities regulatory authority or stock exchange.

 

(c)
Corporate Proceedings. All corporate proceedings and other legal matters in connection with this Agreement, the Transaction Documents,
and the registration or exemption therefrom, sale and delivery of the Securities, shall have been completed or resolved in a manner reasonably
satisfactory to the Placement Agent Counsel, and such counsel shall have been furnished with such papers and information as it may reasonably
have requested to enable such counsel to pass upon the matters referred to in this Section 5.

 

(d)
No Material Adverse Change. Subsequent to the execution and delivery of this Agreement and prior to the Closing Date (if there
shall be more than one Closing Date then prior to each Closing Date), in the Placement Agent’s sole judgment after consultation
with the Company, there shall not have occurred any Material Adverse Effect (as defined in the Purchase Agreement).

 

(e)
Secretary’s Certificate. At the Closing Date (if there shall be more than one Closing Date then at each Closing Date), the
Placement Agent shall have received a certificate of the Company signed by the Secretary of the Company, dated the Closing Date certifying:
(i) that each of the Company’s charter and bylaws is true and complete, has not been modified and is in full force and effect;
(ii) that the resolutions of the Company’s Board of Directors relating to the Offering are in full force and effect and have not
been modified; (iii) as to the accuracy and completeness of all correspondence between the Company or its counsel and the Commission;
and (iv) as to the incumbency of the officers of the Company. The documents referred to in such certificate shall be attached to such
certificate.

 

(f)
Officer’s Certificate. The Placement Agent shall have received on the Closing Date (if there shall be more than one Closing
Date then on each Closing Date) a certificate of the Company, dated as of such Closing Date, signed by the Chief Executive Officer and
Chief Financial Officer of the Company, to the effect that, and the Placement Agent shall be satisfied that, the signers of such certificate
have reviewed this Agreement and the Transaction Documents and to the further effect that:

 

    	 

    	 

    

 

(g)
Stock Exchange Listing. The Common Stock shall be registered under the Exchange Act and shall be if and as applicable, either
admitted for quotation or listed on the Trading Market, and the Company shall not have taken any action designed to terminate, or likely
to have the effect of terminating, the registration of the Common Stock under the Exchange Act or termination of quotation, delisting
or suspending from trading the Common Stock from the Trading Market, nor shall the Company have received any information suggesting that
the Commission or the Trading Market is contemplating terminating such registration, quotation, or listing.

 

(h)
Placement Agent’s Warrant Agreements. On or before the Closing Date (if there shall be more than one Closing Date then on
or before each Closing Date), the Placement Agent shall have received executed copies of the Placement Agent’s Warrant Agreements,
provided the Company has received the Placement Agent’s designees for such Warrant Agreements at least two (2) business days prior
to Closing Date.

 

(i)
Additional Documents. On or before each Closing Date (if there shall be more than one Closing Date then on or before each Closing
Date), the Placement Agent and counsel for the Placement Agent shall have received such information and documents as they may reasonably
require for the purposes of enabling them to pass upon the issuance and sale of the Securities as contemplated herein, or in order to
evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein
contained.

 

(j)
Opinion of Counsel. On or before each Closing Date (if there shall be more than one Closing Date then on or before each Closing
Date), an opinion of Bevilaqua PLLC, counsel to the Company, in form and substance satisfactory to the Placement Agent.

 

If
any condition specified in this Section 5 is not satisfied when and as required to be satisfied, this Agreement may be terminated by
the Placement Agent by notice to the Company at any time on or prior to a Closing Date, which termination shall be without liability
on the part of any party to any other party, except that Section 6 (Payment of Expenses), Section 7 (Indemnification and Contribution)
and Section 8 (Representations and Indemnities to Survive Delivery) shall at all times be effective and shall survive such termination.

 

Section
6. Payment of Expenses. The Company agrees to pay all actual and reasonable costs, fees and expenses incurred by the Company in connection
with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including, without limitation:
(i) all expenses incident to the issuance, delivery and qualification of the Securities (including all printing and engraving costs);
(ii) all fees and expenses of the registrar and transfer agent of the Common Stock; (iii) all necessary issue, transfer and other stamp
taxes in connection with the issuance and sale of the Securities; (iv) all fees and expenses of the Company’s counsel, independent
public or certified public accountants and other advisors; (v) all costs and expenses incurred in connection with the preparation, printing,
filing, shipping and distribution of the Transaction Documents, and all amendments and supplements thereto, and this Agreement; (vi)
all filing fees, reasonable attorneys’ fees and expenses incurred by the Company or the Placement Agent in connection with qualifying
or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Securities for offer and sale
under the state securities or blue sky laws or the securities laws of any other country; (vii) the fees and expenses associated with
including the Securities on the Trading Market; and (viii) the fees and expenses of the Placement Agent’s due diligence; and legal
counsel; provided, however, the maximum amount of this reimbursement for clause (viii) shall in an aggregate amount not
to exceed $60,000 if the gross amount raised is $6 Million and in an aggregate amount not to exceed $100,000 if the gross amount raised
is over $6 Million; unless, with respect to one of more of clauses (i) – (viii) the Company otherwise agrees in writing, and if
the Offering is terminated without a Closing then such amount shall not exceed $35,000.

 

    	 

    	 

    

 

Section
7. Indemnification and Contribution.

 

(a)
The Company agrees to indemnify and hold harmless the Placement Agent, its Affiliates and each person controlling the Placement Agent
(within the meaning of Section 15 of the Securities Act), and the directors, officers, agents and employees of the Placement Agent, its
Affiliates and each such controlling person (the Placement Agent, and each such entity or person, an “Indemnified Person”)
from and against any losses, claims, damages, judgments, assessments, costs and other liabilities (collectively, the “Liabilities”),
and shall reimburse each Indemnified Person for all fees and expenses (including the reasonable fees and expenses of one counsel for
all Indemnified Persons, except as otherwise expressly provided herein) (collectively, the “Expenses”) as they are
incurred by an Indemnified Person in investigating, preparing, pursuing or defending any Actions, whether or not any Indemnified Person
is a party thereto, (i) caused by, or arising out of or in connection with, any untrue statement or alleged untrue statement of a material
fact contained in any Transaction Document or by any omission or alleged omission to state therein a material fact necessary to make
the statements therein, in light of the circumstances under which they were made, not misleading (other than untrue statements or alleged
untrue statements in, or omissions or alleged omissions from, information relating to an Indemnified Person furnished in writing by or
on behalf of such Indemnified Person expressly for use in the Transaction Documents) or (ii) otherwise arising out of or in connection
with advice or services rendered or to be rendered by any Indemnified Person pursuant to this Agreement, the transactions contemplated
thereby or any Indemnified Person’s actions or inactions in connection with any such advice, services or transactions; provided,
however, that, the Company shall not be responsible for any Liabilities or Expenses of any Indemnified Person that are finally
judicially determined to have resulted solely from such Indemnified Person’s (x) gross negligence or willful misconduct in connection
with any of the advice, actions, inactions or services referred to above or (y) use of any offering materials or information concerning
the Company in connection with the offer or sale of the Securities in the Offering which were not authorized for such use by the Company
and which use constitutes gross negligence or willful misconduct. The Company also agrees to reimburse each Indemnified Person for all
Expenses as they are incurred in connection with enforcing such Indemnified Person’s rights under this Agreement.

 

(b)
Upon receipt by an Indemnified Person of actual notice of an Action against such Indemnified Person with respect to which indemnity may
be sought under this Agreement, such Indemnified Person shall promptly notify the Company in writing; provided that failure by any Indemnified
Person so to notify the Company shall not relieve the Company from any liability which the Company may have on account of this indemnity
or otherwise to such Indemnified Person, except to the extent the Company shall have been prejudiced by such failure. The Company shall,
if requested by the Placement Agent, assume the defense of any such Action including the employment of counsel reasonably satisfactory
to the Placement Agent, which counsel may also be counsel to the Company. Any Indemnified Person shall have the right to employ separate
counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense
of such Indemnified Person unless: (i) the Company has failed promptly to assume the defense and employ counsel or (ii) the named parties
to any such Action (including any impeded parties) include such Indemnified Person and the Company, and such Indemnified Person shall
have been advised in the reasonable opinion of counsel that there is an actual conflict of interest that prevents the counsel selected
by the Company from representing both the Company (or another client of such counsel) and any Indemnified Person; provided that the Company
shall not in such event be responsible hereunder for the fees and expenses of more than one firm of separate counsel for all Indemnified
Persons in connection with any Action or related Actions (as defined herein), in addition to any local counsel. The Company shall not
be liable for any settlement of any Action effected without its written consent (which shall not be unreasonably withheld). In addition,
the Company shall not, without the prior written consent of the Placement Agent (which shall not be unreasonably withheld), settle, compromise
or consent to the entry of any judgment in or otherwise seek to terminate any pending or threatened Action in respect of which indemnification
or contribution may be sought hereunder (whether or not such Indemnified Person is a party thereto) unless such settlement, compromise,
consent or termination includes an unconditional release of each Indemnified Person from all Liabilities arising out of such Action for
which indemnification or contribution may be sought hereunder. The indemnification required hereby shall be made by periodic payments
of the amount thereof during the course of the investigation or defense, as such expense, loss, damage or liability is incurred and is
due and payable. “Action” means any action, suit, inquiry, notice of violation, proceeding or investigation affecting
the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative
agency or regulatory authority (federal, state, county, local or foreign).

 

    	 

    	 

    

 

(c)
In the event that the foregoing indemnity is unavailable to an Indemnified Person other than in accordance with this Agreement, the Company
shall contribute to the Liabilities and Expenses paid or payable by such Indemnified Person in such proportion as is appropriate to reflect
(i) the relative benefits to the Company, on the one hand, and to the Placement Agent and any other Indemnified Person, on the other
hand, of the matters contemplated by this Agreement or (ii) if the allocation provided by the immediately preceding clause is not permitted
by applicable law, not only such relative benefits but also the relative fault of the Company, on the one hand, and the Placement Agent
and any other Indemnified Person, on the other hand, in connection with the matters as to which such Liabilities or Expenses relate,
as well as any other relevant equitable considerations; provided that in no event shall the Company contribute less than the amount necessary
to ensure that all Indemnified Persons, in the aggregate, are not liable for any Liabilities and Expenses in excess of the amount of
fees actually received by the Placement Agent pursuant to this Agreement. For purposes of this paragraph, the relative benefits to the
Company, on the one hand, and to the Placement Agent on the other hand, of the matters contemplated by this Agreement shall be deemed
to be in the same proportion as (a) the total value paid or contemplated to be paid to or received or contemplated to be received by
the Company in the transaction or transactions that are within the scope of this Agreement, whether or not any such transaction is consummated,
bears to (b) the fees paid to the Placement Agent under this Agreement. Notwithstanding the above, no person guilty of fraudulent misrepresentation
within the meaning of Section 11(f) of the Securities Act, as amended, shall be entitled to contribution from a party who was not guilty
of fraudulent misrepresentation.

 

(d)
The Company also agrees that no Indemnified Person shall have any liability (whether direct or indirect, in contract or tort or otherwise)
to the Company for or in connection with advice or services rendered or to be rendered by any Indemnified Person pursuant to this Agreement,
the transactions contemplated thereby or any Indemnified Person’s actions or inactions in connection with any such advice, services
or transactions except for Liabilities (and related Expenses) of the Company that are finally judicially determined to have resulted
solely from such Indemnified Person’s gross negligence or willful misconduct in connection with any such advice, actions, inactions
or services.

 

(e)
The reimbursement, indemnity and contribution obligations of the Company set forth herein shall apply to any modification of this Agreement
and shall remain in full force and effect regardless of any termination of, or the completion of any Indemnified Person’s services
under or in connection with, this Agreement.

 

Section
8. Representations and Indemnities to Survive Delivery. The respective indemnities, agreements, representations, warranties and other
statements of the Company or any person controlling the Company, of its officers, and of the Placement Agent set forth in or made pursuant
to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Placement Agent,
the Company, or any of its or their partners, officers or directors or any controlling person, as the case may be, and will survive delivery
of and payment for the Securities sold hereunder and any termination of this Agreement. A successor to the Placement Agent, or to the
Company, its directors or officers or any person controlling the Company, shall be entitled to the benefits of the indemnity, contribution
and reimbursement agreements contained in this Agreement.

 

Section
9. Notices. All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the
parties hereto as follows:

 

If
to the Placement Agent to:

 

Univest
Securities LLC

Investment
Banking

375
Park Avenue, 15th Fl.

New
York, New York 10152

Attention:
Bradley Richmond

Email:
brichmond@univest.us

 

With
a copy to:

 

Sullivan
& Worcester, LLP

1633
Broadway

New
York, New York 10019

Attention:
David Danovitch, Esq.

Email:
Ddanovitch@sullivanlaw.com

 

    	 

    	 

    

 

If
to the Company:

 

555
Heritage Drive, Suite 205

Jupiter,
Florida 33458

Attention:
James Sapirstein, Interim CEO

Email:
JSapirstein@marizyme.com

 

with
a copy (for informational purposes only) to:

 

Bevilacqua
PLLC

1050
Connecticut Ave NW #500

Washington,
DC 20036

Attention:
Louis A. Bevilacqua, Esq.

Email:
lou@bevilacquapllc.com

 

Any
party hereto may change the address for receipt of communications by giving written notice to the others.

 

Section
10. Right of First Refusal and Participation Rights. Subject to consummation of the Offering, if, from the date hereof until the
12-month anniversary following the consummation of the Offering (the “ROFR Period”), the Company or any of its subsidiaries
decides to raise funds by means of a public offering (including at-the-market facility) or a private placement or any other capital raising
financing of equity or equity-linked securities using an underwriter or placement agent, the Placement Agent (or any affiliate designated
by the Placement Agent) shall have the right to act as an underwriter or sole placement agent for such financing. If the Placement Agent
or one of its affiliates decides to accept any such engagement, the agreement governing such engagement will contain, among other things,
provisions for customary fees for transactions of similar size and nature and the provisions of this Agreement, including indemnification,
which are appropriate to such a transaction.

 

Section
11. Successors. This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees,
officers and directors and controlling persons referred to in Section 7 hereof, and to their respective successors, and personal representative,
and no other person will have any right or obligation hereunder.

 

Section
12. Partial Unenforceability. The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not
affect the validity or enforceability of any other section, paragraph or provision hereof. If any Section, paragraph or provision of
this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and
only such minor changes) as are necessary to make it valid and enforceable.

 

Section
13. Governing Law Provisions. This Agreement shall be deemed to have been made and delivered in New York City and both this Agreement
and the transactions contemplated hereby shall be governed as to validity, interpretation, construction, effect and in all other respects
by the internal laws of the State of New York, without regard to the conflict of laws principles thereof. Each of the Placement Agent
and the Company: (i) agrees that any legal suit, action or proceeding arising out of or relating to this Agreement and/or the transactions
contemplated hereby shall be instituted exclusively in New York Supreme Court, County of New York, or in the United States District Court
for the Southern District of New York, (ii) waives any objection which it may have or hereafter to the venue of any such suit, action
or proceeding, and (iii) irrevocably consents to the jurisdiction of the New York Supreme Court, County of New York, and the United States
District Court for the Southern District of New York in any such suit, action or proceeding. Each of the Placement Agent and the Company
further agrees to accept and acknowledge service of any and all process which may be served in any such suit, action or proceeding in
the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York and agrees
that service of process upon the Company mailed by certified mail to the Company’s address shall be deemed in every respect effective
service of process upon the Company, in any such suit, action or proceeding, and service of process upon the Placement Agent mailed by
certified mail to the Placement Agent’s address shall be deemed in every respect effective service process upon the Placement Agent,
in any such suit, action or proceeding. Notwithstanding any provision of this Agreement to the contrary, the Company agrees that neither
the Placement Agent nor its Affiliates, and the respective officers, directors, employees, agents and representatives of the Placement
Agent, its Affiliates and each other person, if any, controlling the Placement Agent or any of its Affiliates, shall have any liability
(whether direct or indirect, in contract or tort or otherwise) to the Company for or in connection with the engagement and transaction
described herein except for any such liability for losses, claims, damages or liabilities incurred by us that are finally judicially
determined to have resulted from the bad faith or gross negligence of such individuals or entities. If either party shall commence an
action or proceeding to enforce any provision of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed
by the other party for its reasonable attorney’s fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such action or proceeding.

 

    	 

    	 

    

 

Section
14. General Provisions.

 

(a)
This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous
oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in two or
more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the
same instrument. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein
(express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. Section headings herein
are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.

 

(b)
The Company acknowledges that in connection with the offering of the Securities: (i) the Placement Agent has acted at arms’ length,
are not agents of, and owe no fiduciary duties to the Company or any other person, (ii) the Placement Agent owes the Company only those
duties and obligations set forth in this Agreement and (iii) the Placement Agent may have interests that differ from those of the Company.
The Company waives to the full extent permitted by applicable law any claims it may have against the Placement Agent arising from an
alleged breach of fiduciary duty in connection with the offering of the Securities.

 

Section
15. Fee Tail. The Placement Agent shall be entitled to the cash fees and Placement Agent’s Warrants calculated in the manner
described in Section 1 hereto with respect to any private or public offering or other financing or capital raising transaction of any
kind consummated within 12 months period of the termination or expiration of this Agreement with an investor whom the Placement Agent
has, directly or indirectly, introduced to the Company during the term of this Agreement.

 

[The
remainder of this page has been intentionally left blank.]

 

    	 

    	 

    

 

If
the foregoing is in accordance with your understanding of our agreement, please sign below whereupon this instrument, along with all
counterparts hereof, shall become a binding agreement in accordance with its terms.

 

Accepted
and Agreed to as of

the
date first written above:

 

	UNIVEST
                                            SECURITIES LLC

	 
	 	 	 
	By:
    		 
	Name:	Yi
    (Edric) Guo	 
	Title:	Chief
    Operating Officer	 
	 	 	 
	Address
    for notice:	 
	375
    Park Avenue	 
	New
    York, New York 10152	 
	Attention:
                                            Yi (Edric) Guo

Email:

	 
	 	 	 
	MARIZYME
    INC.	 
	 	 	 
	By:
    		 
	Name:	 	 
	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]